Current Report Filing (8-k)
March 04 2020 - 2:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 4, 2020
Baudax Bio, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
001-39101
|
|
47-4639500
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
490 Lapp Road, Malvern, Pennsylvania
|
|
19355
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (484)
395-2470
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading
Symbol
|
|
Name of Exchange
on Which Registered
|
Common Stock, par value $0.01
|
|
BXRX
|
|
Nasdaq Capital Market
|
Securities registered pursuant to Section 12(g) of the Act: None
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
On March 4, 2020, Baudax Bio (the Company) issued a press release announcing that it has signed a
non-binding term sheet with an undisclosed lender for a secured term loan up to $20 million. The Company intends to draw on the term loan to fund the commercial launch of ANJESOTM in the United States. A copy of the press release is attached hereto as Exhibit 99.1, and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibits are being filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
Baudax Bio, Inc.
|
|
|
By:
|
|
/s/ Gerri A. Henwood
|
Name:
|
|
Gerri A. Henwood
|
Title:
|
|
President and Chief Executive Officer
|
Date: March 4, 2020
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From May 2024 to May 2024
Baudax Bio (NASDAQ:BXRXV)
Historical Stock Chart
From May 2023 to May 2024